Neovascular Age-related Macular Degeneration | JEP
Pipeline Report: Despite major approvals, the queue gets longer
Anti VEFG Agents In Retinal Diseases
Cost-effectiveness of intravitreal conbercept versus other treatments for wet age-related macular degeneration - Chen - Annals of Translational Medicine
Retinal Physician - The Phase 3 Clinical Trial of Conbercept for Exudative AMD
Pipeline Report: New entries continue to exceed exits
Our Ophthalmic Studies – Cascade Medical Research Institute
2023: The year of geographic atrophy
panda
Phase III Trials in Wet AMD—What's Next?
Chengdu Kanghongs' Phase III ophthalmic agent drops 7 points in AMD
Phase III Trials in Wet AMD—What's Next?
Tracking the treatments of tomorrow.
IJMS | Free Full-Text | Ocular Therapeutics and Molecular Delivery Strategies for Neovascular Age-Related Macular Degeneration (nAMD)
Anti-VEGF: Where Are We Now?
Retinal Physician : October 2019
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept | BioSpace
Phase III Trials in Wet AMD—What's Next?
The Retina Center
Full article: Investigational drugs in clinical trials for macular degeneration
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma | Eye
Technology name [formulation]* for indication [– first/second/third line]*
More Patients Set to Benefit as Kanghong Pharmaceutical Targets New Indications with Conbercept
The Efficacy of Conbercept in Polypoidal Choroidal Vasculopathy: A Systematic Review. - Document - Gale Academic OneFile
Molecules | Free Full-Text | Recent Advances in Age-Related Macular Degeneration Therapies
Conbercept was constructed by fusing the the second Ig-like domain of... | Download Scientific Diagram
Emerging Treatments for Neovascular AMD - Retina Today
Journey West: How One Small Chinese Firm Is Taking On The World :: Scrip
RetinaToday | Treatment Adherence in Neovascular AMD
